Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ADRB2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METAPROTERENOL | ↑ activates | Mechanistic | DGIdb | |
| PROPRANOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| OLODATEROL | ↑ activates | Mechanistic | DGIdb | |
| TIMOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1465049 | ? unclear | Mechanistic | DGIdb | |
| NOREPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| EPHEDRINE SULFATE | ↑ activates | Mechanistic | DGIdb | |
| LEVALBUTEROL | ? unclear | Mechanistic | DGIdb | |
| 3-O-METHYLQUERCETIN | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| CLENBUTEROL | ↑ activates | Mechanistic | DGIdb | |
| ARFORMOTEROL | ? unclear | Mechanistic | DGIdb | |
| CELIPROLOL | ↑ activates | Mechanistic | DGIdb | |
| ISOPROTERENOL | ↑ activates | Mechanistic | 0.1585 nM (EC50) | DGIdb |
| MEPHENTERMINE SULFATE | ↑ activates | Mechanistic | DGIdb | |
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| PROCATEROL | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL590927 | ? unclear | Mechanistic | DGIdb | |
| TERTATOLOL | ? unclear | Mechanistic | DGIdb | |
| FENOTEROL | ↑ activates | Mechanistic | DGIdb | |
| MEPINDOLOL | ? unclear | Mechanistic | DGIdb | |
| PROPAFENONE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL531322 | ? unclear | Mechanistic | DGIdb | |
| CARMOTEROL | ↑ activates | Mechanistic | DGIdb | |
| PINDOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| SALMETEROL | ↑ activates | Mechanistic | DGIdb | |
| CGP12177 | ↓ inhibits | Mechanistic | DGIdb | |
| CLENBUTEROL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NADOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| DESIPRAMINE | ? unclear | Mechanistic | DGIdb | |
| CIMATEROL | ↑ activates | Mechanistic | DGIdb | |
| FENOTEROL HBR | ? unclear | Mechanistic | DGIdb | |
| RITODRINE | ? unclear | Mechanistic | DGIdb | |
| PF-00610355 | ? unclear | Mechanistic | DGIdb | |
| SOTALOL | ↓ inhibits | Mechanistic | DGIdb | |
| TERBUTALINE | ↑ activates | Mechanistic | DGIdb | |
| LAS190792 | ↑ activates | Mechanistic | DGIdb | |
| NORADRENALINE | ↑ activates | Mechanistic | DGIdb | |
| LEVOBUNOLOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PENBUTOLOL SULFATE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 368 agents ranked by evidence tier.
ADRB3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FENOTEROL | ↑ activates | Mechanistic | DGIdb | |
| MIRABEGRON | ↑ activates | Mechanistic | DGIdb | |
| RAFABEGRON | ↑ activates | Mechanistic | 0.062 nM (EC50) | DGIdb |
| CGP12177 | ↑ activates | Mechanistic | DGIdb | |
| NIPRADILOL | ? unclear | Mechanistic | DGIdb | |
| TRIHEXYPHENIDYL | ? unclear | Mechanistic | DGIdb | |
| ISOPROTERENOL | ↑ activates | Mechanistic | 1000.0 nM (EC50) | DGIdb |
| BOPINDOLOL | ? unclear | Mechanistic | DGIdb | |
| AMOSULALOL | ? unclear | Mechanistic | DGIdb | |
| CARVEDILOL | ↓ inhibits | Mechanistic | DGIdb | |
| NOREPINEPHRINE BITARTRATE | ↑ activates | Mechanistic | DGIdb | |
| EPHEDRINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| L742791 | ↑ activates | Mechanistic | DGIdb | |
| EPINEPHRINE BITARTRATE | ↑ activates | Mechanistic | DGIdb | |
| LY-377604 | ? unclear | Mechanistic | DGIdb | |
| TALIBEGRON HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| PINDOLOL | ↓ inhibits | Mechanistic | DGIdb | |
| VIBEGRON | ↑ activates | Mechanistic | DGIdb | |
| MN-246 | ? unclear | Mechanistic | DGIdb | |
| EPHEDRINE SULFATE | ↑ activates | Mechanistic | DGIdb | |
| EPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| L 755507 | ↑ activates | Mechanistic | DGIdb | |
| DILEVALOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CARVEDILOL PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| RIMITEROL | ? unclear | Mechanistic | DGIdb | |
| BITOLTEROL | ? unclear | Mechanistic | DGIdb | |
| CARAZOLOL | ↑ activates | Mechanistic | DGIdb | |
| DROXIDOPA | ↑ activates | Mechanistic | DGIdb | |
| LY377604 | ↑ activates | Mechanistic | DGIdb | |
| SOLABEGRON | ↑ activates | Mechanistic | DGIdb | |
| NOREPINEPHRINE | ↑ activates | Mechanistic | DGIdb | |
| AMIBEGRON | ↑ activates | Mechanistic | DGIdb | |
| L-748337 | ↓ inhibits | Mechanistic | DGIdb | |
| LABETALOL HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CL316243 | ↑ activates | Mechanistic | DGIdb | |
| ISOPROTERENOL SULFATE | ↑ activates | Mechanistic | DGIdb | |
| ISOPROTERENOL HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ABEDITEROL | ↑ activates | Mechanistic | DGIdb | |
| ICI118551 | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]L748337 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 255 agents ranked by evidence tier.
CHRM2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TIOTROPIUM | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]OXOTREMORINE-M | ↑ activates | Mechanistic | DGIdb | |
| SOFPIRONIUM BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ASM-024 | ↓ inhibits | Mechanistic | DGIdb | |
| FESOTERODINE FUMARATE | ↓ inhibits | Mechanistic | DGIdb | |
| PROMAZINE | ? unclear | Mechanistic | DGIdb | |
| STAUROSPORINE | ~ modulates | Mechanistic | DGIdb | |
| ZAMIFENACIN | ? unclear | Mechanistic | DGIdb | |
| WIN 51,708 | ~ modulates | Mechanistic | DGIdb | |
| ALCURONIUM | ~ modulates | Mechanistic | DGIdb | |
| MEPENZOLATE | ↓ inhibits | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| HEXOCYCLIUM | ↓ inhibits | Mechanistic | DGIdb | |
| HEXAHYDROSILADIFENIDOL | ↓ inhibits | Mechanistic | DGIdb | |
| IPRATROPIUM CATION | ↓ inhibits | Mechanistic | DGIdb | |
| ARECOLINE | ↑ activates | Mechanistic | 40.0 nM (Ki) | DGIdb |
| AE9C90CB | ↓ inhibits | Mechanistic | DGIdb | |
| WDUO3 | ~ modulates | Mechanistic | DGIdb | |
| BETHANECHOL | ↑ activates | Mechanistic | DGIdb | |
| MIVACURIUM | ? unclear | Mechanistic | DGIdb | |
| PILOCARPINE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| [3H]N-METHYL SCOPOLAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| ALEXA-488-TELENZEPINE | ↓ inhibits | Mechanistic | DGIdb | |
| THIETHYLPERAZINE | ? unclear | Mechanistic | DGIdb | |
| ARECAIDINE PROPARGYL ESTER | ↑ activates | Mechanistic | DGIdb | |
| N-CHLOROMETHYL-BRUCINE | ~ modulates | Mechanistic | DGIdb | |
| P-F-HHSID | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]QNB | ↓ inhibits | Mechanistic | DGIdb | |
| TRIDIHEXETHYL | ? unclear | Mechanistic | DGIdb | |
| NNC 11-1585 | ↑ activates | Mechanistic | DGIdb | |
| DARIFENACIN | ↓ inhibits | Mechanistic | DGIdb | |
| PROPANTHELINE BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PIPERTRAMINE AMIDE | ? unclear | Mechanistic | DGIdb | |
| PIRENZEPINE | ↓ inhibits | Mechanistic | DGIdb | |
| TRIFLUPROMAZINE | ? unclear | Mechanistic | DGIdb | |
| METHOTRIMEPRAZINE | ? unclear | Mechanistic | DGIdb | |
| ML381 | ↓ inhibits | Mechanistic | DGIdb | |
| SILAHEXOCYCLIUM | ↓ inhibits | Mechanistic | DGIdb | |
| BAY2413555 | ~ modulates | Mechanistic | DGIdb | |
| VINBURNINE | ~ modulates | Mechanistic | DGIdb |
Showing top 40 of 317 agents ranked by evidence tier.
CHRM3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| OCTOTROPINE METHYLBROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TIOTROPIUM | ↓ inhibits | Mechanistic | DGIdb | |
| BETHANECHOL CHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| GLYCOPYRRONIUM TOSYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| REVEFENACIN | ↓ inhibits | Mechanistic | DGIdb | |
| OXYBUTYNIN | ↓ inhibits | Mechanistic | DGIdb | |
| MUSCARINIC TOXIN 7 | ↓ inhibits | Mechanistic | DGIdb | |
| SOLIFENACIN | ↓ inhibits | Mechanistic | DGIdb | |
| ZAMIFENACIN | ? unclear | Mechanistic | DGIdb | |
| UMECLIDINIUM BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ACLIDINIUM | ↓ inhibits | Mechanistic | DGIdb | |
| PROPIOMAZINE | ? unclear | Mechanistic | DGIdb | |
| (S)-DIMETINDENE | ↓ inhibits | Mechanistic | DGIdb | |
| TERODILINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| IPRATROPIUM CATION | ↓ inhibits | Mechanistic | DGIdb | |
| PENTYLTHIO-TZTP | ↑ activates | Mechanistic | DGIdb | |
| CARBAMOYLCHOLINE | ↑ activates | Mechanistic | DGIdb | |
| IPRATROPIUM BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DIPHENIDOL | ? unclear | Mechanistic | DGIdb | |
| METHYLHOMATROPINE | ? unclear | Mechanistic | DGIdb | |
| PROMAZINE | ? unclear | Mechanistic | DGIdb | |
| METHSCOPOLAMINE BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ACETYLCHOLINE CHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| TROPICAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| AZD8683 | ↓ inhibits | Mechanistic | DGIdb | |
| PIPERTRAMINE | ? unclear | Mechanistic | DGIdb | |
| TRIDIHEXETHYL | ? unclear | Mechanistic | DGIdb | |
| MEPENZOLATE BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TOLTERODINE | ↓ inhibits | Mechanistic | DGIdb | |
| FESOTERODINE | ? unclear | Mechanistic | DGIdb | |
| HEXOCYCLIUM METHYLSULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| SUCCINYLCHOLINE | ? unclear | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| SOFPIRONIUM BROMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]TIOTROPIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ML381 | ↓ inhibits | Mechanistic | DGIdb | |
| PIPERTRAMINE AMIDE | ? unclear | Mechanistic | DGIdb | |
| MEPENZOLATE | ↓ inhibits | Mechanistic | DGIdb | |
| ACECLIDINE | ↑ activates | Mechanistic | DGIdb | |
| OXOTREMORINE | ↑ activates | Mechanistic | 210.0 nM (EC50) | DGIdb |
Showing top 40 of 333 agents ranked by evidence tier.
P2RX3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FILAPIXANT | ↓ inhibits | Mechanistic | DGIdb | |
| GEFAPIXANT | ↓ inhibits | Mechanistic | DGIdb | |
| SURAMIN | ↓ inhibits | Mechanistic | 3000.0 nM (EC50) | DGIdb |
| CAMLIPIXANT | ↓ inhibits | Mechanistic | DGIdb | |
| RO3 | ↓ inhibits | Mechanistic | DGIdb | |
| BZATP | ↑ activates | Mechanistic | DGIdb | |
| ΑΒ-MEATP | ↑ activates | Mechanistic | DGIdb | |
| AF353 | ↓ inhibits | Mechanistic | DGIdb | |
| ELIAPIXANT | ↓ inhibits | Mechanistic | DGIdb | |
| ADENOSINE TRIPHOSPHATE | ↑ activates | Mechanistic | 340.0 nM (EC50) | DGIdb |
| A317491 | ↓ inhibits | Mechanistic | DGIdb | |
| AF-906 | ↓ inhibits | Mechanistic | DGIdb | |
| TNP-ATP | ↓ inhibits | Mechanistic | 0.9 nM (EC50) | DGIdb |
| SIVOPIXANT | ↓ inhibits | Mechanistic | DGIdb | |
| SPINORPHIN | ~ modulates | Mechanistic | 0.0481 nM (IC50) | DGIdb |
| GEFAPIXANT CITRATE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL335206 | ↑ activates | Mechanistic | 8800.0 nM (EC50) | ChEMBL |
| CHEMBL1628528 | ↓ inhibits | Mechanistic | 2800.0 nM (IC50) | ChEMBL |
| CHEMBL339386 | ↑ activates | Mechanistic | 80.0 nM (EC50) | ChEMBL |
| PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER | ↑ activates | Mechanistic | 9200.0 nM (EC50) | ChEMBL |
| CHEMBL216504 | ↓ inhibits | Mechanistic | 28500.0 nM (IC50) | ChEMBL |
| DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER | ↑ activates | Mechanistic | 740.0 nM (EC50) | ChEMBL |
| ATPGAMMAS | ↑ activates | Mechanistic | 690.0 nM (EC50) | ChEMBL |
| CHEMBL129841 | ↑ activates | Mechanistic | 13000.0 nM (EC50) | ChEMBL |
| ISOPPADS | ↓ inhibits | Mechanistic | 84.0 nM (IC50) | ChEMBL |
| CHEMBL74121 | ↓ inhibits | Mechanistic | 58300.0 nM (IC50) | ChEMBL |
| CHEMBL133930 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL130094 | ↑ activates | Mechanistic | 350.0 nM (EC50) | ChEMBL |
| CHEMBL337062 | ↑ activates | Mechanistic | 17.0 nM (EC50) | ChEMBL |
| CHEMBL336208 | ↑ activates | Mechanistic | 350.0 nM (EC50) | ChEMBL |
| CHEMBL69234 | ↑ activates | Mechanistic | 240.0 nM (EC50) | ChEMBL |
| DIADENOSINE TETRAPHOSPHATE | ↑ activates | Mechanistic | 500.0 nM (EC50) | ChEMBL |
| CHEMBL413145 | ↓ inhibits | Mechanistic | 354.81 nM (IC50) | ChEMBL |
| CHEMBL397926 | ↓ inhibits | Mechanistic | 82.4 nM (IC50) | ChEMBL |
| CHEMBL395723 | ↓ inhibits | Mechanistic | 32.4 nM (IC50) | ChEMBL |
| CHEMBL238310 | ↓ inhibits | Mechanistic | 14.3 nM (IC50) | ChEMBL |
| CHEMBL599760 | ↓ inhibits | Mechanistic | 398.11 nM (IC50) | ChEMBL |
| CHEMBL2010928 | ↓ inhibits | Mechanistic | 1360.0 nM (IC50) | ChEMBL |
| CHEMBL2010929 | ↓ inhibits | Mechanistic | 618.0 nM (IC50) | ChEMBL |
| CHEMBL2010930 | ↓ inhibits | Mechanistic | 327.0 nM (IC50) | ChEMBL |
Showing top 40 of 202 agents ranked by evidence tier.
SNAP25
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INCOBOTULINUMTOXINA | ↓ inhibits | Mechanistic | DGIdb | |
| PRABOTULINUMTOXIN A | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC STEROID HORMONE | ? unclear | Mechanistic | DGIdb | |
| AMISULPRIDE | ? unclear | Mechanistic | DGIdb | |
| DAXIBOTULINUMTOXINA | ↓ inhibits | Mechanistic | DGIdb | |
| TRENIBOTULINUMTOXINE | ? unclear | Mechanistic | DGIdb | |
| LETIBOTULINUMTOXINA | ? unclear | Mechanistic | DGIdb | |
| ONABOTULINUMTOXINA | ↓ inhibits | Mechanistic | DGIdb | |
| BOTULINUM TOXIN TYPE A | ? unclear | Mechanistic | DGIdb | |
| DIAZOXIDE | ? unclear | Mechanistic | DGIdb | |
| ABOBOTULINUMTOXINA | ? unclear | Clinical | Open Targets |
TRPA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASP7663 | ↑ activates | Mechanistic | DGIdb | |
| NPPB | ↑ activates | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| METHYLGLYOXAL | ↑ activates | Mechanistic | DGIdb | |
| ALLYL ISOTHIOCYANATE | ↑ activates | Mechanistic | 33500.0 nM (EC50) | DGIdb |
| BENZYL BROMIDE | ↑ activates | Mechanistic | 12000.0 nM (EC50) | DGIdb |
| 1,6-HEXAMETHYLENE DIISOCYANATE | ↑ activates | Mechanistic | DGIdb | |
| BROMOACETONE | ↑ activates | Mechanistic | DGIdb | |
| ACETALDEHYDE | ↑ activates | Mechanistic | DGIdb | |
| ISOVELLERAL | ↑ activates | Mechanistic | 590.0 nM (EC50) | DGIdb |
| POLYGODIAL | ↑ activates | Mechanistic | 59.0 nM (EC50) | DGIdb |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| A-967079 | ↓ inhibits | Mechanistic | DGIdb | |
| NITROOLEIC ACID | ↑ activates | Mechanistic | DGIdb | |
| PHENETHYLISOTHIOCYANATE | ? unclear | Mechanistic | 10000.0 nM (EC50) | DGIdb |
| PF-4840154 | ↑ activates | Mechanistic | DGIdb | |
| 4-HYDROXYNONENAL | ? unclear | Mechanistic | DGIdb | |
| AM-0902 | ↓ inhibits | Mechanistic | DGIdb | |
| ACROLEIN | ↑ activates | Mechanistic | 5000.0 nM (EC50) | DGIdb |
| 1'-ACETOXYCHAVICOL ACETATE | ↑ activates | Mechanistic | DGIdb | |
| GDC-0334 | ↓ inhibits | Mechanistic | DGIdb | |
| METHYL ISOCYANATE | ↑ activates | Mechanistic | DGIdb | |
| BUTAMBEN | ↓ inhibits | Mechanistic | DGIdb | |
| ERUCIN | ? unclear | Mechanistic | DGIdb | |
| CHLOROPICRIN | ↑ activates | Mechanistic | DGIdb | |
| SALIRASIB | ↑ activates | Mechanistic | 5000.0 nM (EC50) | DGIdb |
| BUTAMBEN PICRATE | ↓ inhibits | Mechanistic | DGIdb | |
| MENTHOL | ↑ activates | Mechanistic | 28400.0 nM (EC50) | DGIdb |
| CHLOROBENZYLIDENE MALONONITRILE | ↑ activates | Mechanistic | DGIdb | |
| HC030031 | ↓ inhibits | Mechanistic | DGIdb | |
| URB597 | ↑ activates | Mechanistic | DGIdb | |
| JT010 | ↑ activates | Mechanistic | DGIdb | |
| DIBUTYLPHTHALATE | ↑ activates | Mechanistic | DGIdb | |
| AP18 | ↓ inhibits | Mechanistic | DGIdb | |
| TCS 5861528 | ↓ inhibits | Mechanistic | DGIdb | |
| APOMORPHINE | ↑ activates | Mechanistic | DGIdb | |
| CB-189625 | ↓ inhibits | Mechanistic | DGIdb | |
| BENZOQUINONE | ↑ activates | Mechanistic | DGIdb | |
| GRC-17536 | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 186 agents ranked by evidence tier.
TRPV1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| RHTX | ↑ activates | Mechanistic | DGIdb | |
| ABT-102 | ↓ inhibits | Mechanistic | DGIdb | |
| ASIVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| BCTC | ↓ inhibits | Mechanistic | DGIdb | |
| MAVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| POLYGODIAL | ? unclear | Mechanistic | DGIdb | |
| ALLICIN | ↓ inhibits | Mechanistic | DGIdb | |
| JTS-653 | ↓ inhibits | Mechanistic | DGIdb | |
| SB452533 | ↓ inhibits | Mechanistic | DGIdb | |
| MR-1817 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-6211 | ↓ inhibits | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ↑ activates | Mechanistic | DGIdb | |
| DWP05195 | ↓ inhibits | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| CAPSAICIN | ↑ activates | Mechanistic | 19.95 nM (EC50) | DGIdb |
| AMG517 | ↓ inhibits | Mechanistic | DGIdb | |
| 5S-HETE | ↑ activates | Mechanistic | DGIdb | |
| BENZYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| [3H]RESINIFERATOXIN | ↑ activates | Mechanistic | DGIdb | |
| [3H]A778317 | ↓ inhibits | Mechanistic | DGIdb | |
| CAPSAZEPINE | ↓ inhibits | Mechanistic | 120.0 nM (Ki) | DGIdb |
| NABIXIMOLS | ? unclear | Mechanistic | DGIdb | |
| H+ | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| NADA | ↓ inhibits | Mechanistic | DGIdb | |
| ZUCAPSAICIN | ↑ activates | Mechanistic | DGIdb | |
| SB366791 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-15300 | ? unclear | Mechanistic | DGIdb | |
| MRS-1477 | ~ modulates | Mechanistic | DGIdb | |
| ANANDAMIDE | ↑ activates | Mechanistic | DGIdb | |
| JNJ17203212 | ↓ inhibits | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| AZD1386 | ↓ inhibits | Mechanistic | DGIdb | |
| CAMPHOR OIL | ↑ activates | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| FERRUGINENE B | ? unclear | Mechanistic | DGIdb | |
| PHENYLACETYLRINVANIL | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 187 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Overactive Bladder (OAB): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis med...
A study to evaluate the safety and effectiveness of FemPulse System
This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching p...
The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.
The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women. The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of li...
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg),...
The goal of this Pre-Post Quasi-experimental study is to investigates the effect of vaginal estrogen therapy on changes in the urinary microbiome and its association with improvement in overactive bladder (OAB) symptoms in menopausal women Primary Objective: To evaluate the effects of vaginal estrog...
The aim of this study is to give children with dry OAB: (1) Standard behavioral therapy combined with classical anticholinergic drugs (Solinaxine), or (2) standard behavioral therapy combined with short-term high-dose exogenous vitamin D supplementation are used to compare the outcomes of lower urin...
This is a prospective, randomized controlled clinical trial designed to compare the efficacy and safety of transdermal versus oral oxybutynin in children diagnosed with overactive bladder (OAB) who remain symptomatic despite conservative management. A total of 90 children were planned to be enrolled...
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A...
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes. Study will also be assessed for the pain of procedure and adverse outcomes of 20 inject...
Agents Found By Disease-Level Search
Searched directly from “Overactive Bladder (OAB)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
39 agents shown (approved or with trial evidence) — 30 not found by the gene-target search above.
fesoterodine
Mirabegron
Tolterodine
botulinum toxin Type A
ONO-8539NOT in gene-target list
solifenacin
Oxybutynin
mirabegron (YM178)NOT in gene-target list
Pumpkin Seed ExtractNOT in gene-target list
onabotulinumtoxinA
Fesoterodine fumarate
oxybutynin chloride
Bladder diaryNOT in gene-target list
tarafenacin (SVT-40776)NOT in gene-target list
500 mg NDS-446NOT in gene-target list
Medication GroupNOT in gene-target list
Sativex®NOT in gene-target list
Solifenacin Succinate 5mg/tab dailyNOT in gene-target list
Solifenacin Succinate TabletsNOT in gene-target list
EstrogenNOT in gene-target list
Strain ElastographyNOT in gene-target list
Liposome encapsulated botulinum toxin ANOT in gene-target list
PTNSNOT in gene-target list
Diary pod ( measuring vessel that automatically calculates voided volume)NOT in gene-target list
Conventional fluoroscopyNOT in gene-target list
visceral fat obesity (surface area and function)NOT in gene-target list
Solabegron immediate release tablets, low doseNOT in gene-target list
Solabegron immediate release tablets, high doseNOT in gene-target list
JLP-2002NOT in gene-target list
ComparatorNOT in gene-target list
Injection of Onabotulinum toxinNOT in gene-target list
fesoterodine (SPM 907)NOT in gene-target list
ritobegron (KUC-7483)NOT in gene-target list
Tolterodine tartrate extended release capsulesNOT in gene-target list
Desmopressin orally disintegrating tabletsNOT in gene-target list
Paced RespirationNOT in gene-target list
Music TherapyNOT in gene-target list
Lidocaine patchNOT in gene-target list
JLP-2002 A mgNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.